Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

A systematic review of randomized controlled trials (RCTs) found that weight-loss interventions were associated with improvements in some polycystic ovary syndrome (PCOS) symptoms, including ...

There are a handful of patients in DESTINY-Breast03 with active brain metastasis that were enrolled, and they did look and ...

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Studies have called into question whether patients with HER2-low breast cancer are being identified and classified accurately.

“We are excited to present at EORTC-NCI-AACR with data demonstrating how HMBD-802 can potently treat tumors in T-DXd-insensitive settings whilst maintaining an optimal safety profile. I look forward ...

In their recent study, Dr. Hurvitz and her research team were interested in determining if T-DXd had improved efficacy for patients with BM compared to other treatments. To approach this, they ...

Trastuzumab deruxtecan (T-DXd; Enhertu) is an antibody-drug conjugate used as standard therapy for HER2-positive and HER2-low unresectable or metastatic breast cancer. 1 It is classified by the ...